Longer ‘On’ Time Seen With Infused ABBV-951 Than Oral Levodopa in Trial

Longer ‘On’ Time Seen With Infused ABBV-951 Than Oral Levodopa in Trial

311195

Longer ‘On’ Time Seen With Infused ABBV-951 Than Oral Levodopa in Trial

ABBV-951, an under-the-skin formulation of levodopa/carbidopa, outperformed the standard oral therapy at controlling Parkinson’s symptoms in advanced disease patients in a Phase 3 clinical trial, top-line results show. “These data are promising and demonstrate positive results on a key endpoint used to assess efficacy of treatments for patients with advanced Parkinson’s,” Jason Aldred, MD, a professor at the University of Washington and principal trial investigator, said in a press release. Trial findings will help to support…

You must be logged in to read/download the full post.